License to kill: Retinoic acid programs T cells for tissue residency.

Authors:
Heeg M; Goldrath AW.

Journal:
J Exp Med

Publication Year: 2023

DOI:
10.1084/jem.20230161

PMCID:
PMC10035436

PMID:
36897330

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Addendum: Resolvins suppress tumor growth and enhance cancer therapy.
Sulciner ML; Serhan CN; Gilligan MM and 18 more (2024) - Transparency Score: 2/6
Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-d…
Ruggiu M; Guérin MV; Corre B and 9 more (2024) - Transparency Score: 3/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures: A.W. Goldrath is a member of the SAB of ArsenalBio. No other disclosures were reported."

Evidence found in paper:

"This work is supported in part by grants to A.W. Goldrath from the National Institutes of Health (AI132122 and AI145815)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025